BMS and Concerto HealthAI Agreement Accelerates Precision Oncology Innovations

March 28, 2019

Applied Clinical Trials

The multi-year strategic agreement between Bristol-Myers Squibb and Concerto HealthAI announced will cover a diverse range of cancers, integrate multiple data sources, and apply AI and machine learning to accelerate clinical trials for precision treatment and improved patient outcomes. 

Read the full release here.

Related Content: